Treatments for chronic myeloid leukemia: a qualitative systematic review

References

• HeisterkampNStamKGroffenJde KleinAGrosveldGStructural organization of the bcr gene and its role in the Ph’ translocationNature198531560227587612989703
   PubMed Web of Science ®Google Scholar
• RowleyJDA new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa stainingNature197324354052902934126434
   PubMed Web of Science ®Google Scholar
• PensergaETSkorskiTFusion tyrosine kinases: a result and cause of genomic instabilityOncogene2007261112016785987
   PubMed Web of Science ®Google Scholar
• RohrbacherMHasfordJEpidemiology of chronic myeloid leukaemia (CML)Best Pract Res Clin Haematol200922329530219959081
   PubMed Web of Science ®Google Scholar
• KantarjianHFaderlSTalpazMChronic myelogenous leukemiaDeVitaHellmanRosenbergCancer: Principles and Practice of OncologyPhiladelphiaLippincott Williams & Wilkins2001
   Google Scholar
• DeVitaVLawrenceTRosenbergSDeVita, Hellman, and Rosenberg’s Cancer: Cancer: Principles and Practice of Oncology8th edPhiladelphiaLippincott Williams & Wilkins2008
   Google Scholar
• PavlovskyCKantarjianHCortesJEFirst-line therapy for chronic myeloid leukemia: past, present, and futureAm J Hematol200984528729319306355
   PubMed Web of Science ®Google Scholar
• TraskPCCellaDBessonNKellyVMassziTKimDWHealth- related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemiaLeuk Res201236443844222036634
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCKimDWTurkinaABosutinib (SKI-606) as second-line therapy for chronic phase chronic myeloid leukemia following imatinib failure: analyses of cross-intolerance and response by prior response to imatinib16th Congress of the European Hematology AssociationJune 9–12, 2011London, UK
   Google Scholar
• Gambacorti-PasseriniCBrümmendorfTCortesJBosutinib as third-line therapy for chronic phase chronic myeloid leukemia following failure with imatinib and dasatinib or nilotinib16th Congress of the European Hematology AssociationJune 9–12, 2011London, UK
   Google Scholar
• Gambacorti-PasseriniCKimDWKantarjianHAn ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Abstract 20852nd American Society of Hematology Annual MeetingDecember 10–13, 2010Orlando, FL
   Google Scholar
• Gambacorti-PasseriniCCortesJKhouryHJBosutinib (BOS) versus imatinib (IM) in patients with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. Abstract 6509American Society of Clinical Oncology Annual MeetingJune 3–7, 2011Chicago, IL.
   Google Scholar
• The Cochrane CollaborationCochrane Handbook for Systematic Reviews of Interventions Version 5.1.02011 Available from: http://www.cochrane-handbook.orgAccessed June 26, 2012.
   Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med200334811994100412637609
   PubMed Web of Science ®Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2010362242260227020525995
   PubMed Web of Science ®Google Scholar
• RadichJPKopeckyKJKamel-ReidSA randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup Trial52nd American Society of Hematology Annual Meeting and ExpositionDecember 4–7, 2010Orlando, FL
   Google Scholar
• SaglioGKimDWIssaragrisilSNilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med2010362242251225920525993
   PubMed Web of Science ®Google Scholar
• CortesJEBaccaraniMGuilhotFPhase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJ Clin Oncol201028342443020008622
   PubMed Web of Science ®Google Scholar
• BaccaraniMDrukerBCortesJ24 months update of the TOPS study: a phase iii, randomized open label study of 400 mg/d (SD-IM) versus 800 mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously treated chronic myeloid leukemia in chronic phase (CML-CP). Abstract 33751st American Society of Hematology Annual Meeting and ExpositionDecember 5–8, 2009New Orleans, LA
   Google Scholar
• CortesJEJonesDO’BrienSResults of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemiaJ Clin Oncol201028339840420008620
   PubMed Web of Science ®Google Scholar
• KantarjianHPasquiniRHamerschlakNDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialBlood2007109125143515017317857
   PubMed Web of Science ®Google Scholar
• KantarjianHCortesJKimDWPhase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-upBlood2009113256322632919369231
   PubMed Web of Science ®Google Scholar
• ShahNPKantarjianHMKimDWIntermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaJ Clin Oncol200826193204321218541900
   PubMed Web of Science ®Google Scholar
• KantarjianHPasquiniRLevyVDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Cancer2009115184136414719536906
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood200710962303230917138817
   PubMed Web of Science ®Google Scholar
• GuilhotFApperleyJKimDWDasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood2007109104143415017264298
   PubMed Web of Science ®Google Scholar
• CortesJRousselotPKimDWDasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood200710983207321317185463
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantarjianHDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med2006354242531254116775234
   PubMed Web of Science ®Google Scholar
• OttmannODombretHMartinelliGDasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyBlood200711072309231517496201
   PubMed Web of Science ®Google Scholar
• MauroMJBaccaraniMCervantesFDasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)J Clin Oncol200826May 20 SupplAbstr 7009
   Web of Science ®Google Scholar
• KantarjianHMGilesFGattermannNNilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood2007110103540354617715389
   PubMed Web of Science ®Google Scholar
• GilesFJAbruzzeseERostiGNilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyLeukemia20102471299130120520639
   PubMed Web of Science ®Google Scholar
• IbrahimARPaliompeisCBuaMEfficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyBlood2010116255497550020833982
   PubMed Web of Science ®Google Scholar
• GargRJKantarjianHO’BrienSThe use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upBlood2009114204361436819729517
   PubMed Web of Science ®Google Scholar
• KantarjianHMLarsonRAGuilhotFEfficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phaseCancer2009115355156019117345
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
   PubMed Web of Science ®Google Scholar
• HochhausAO’BrienSGGuilhotFSix-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia20092361054106119282833
   PubMed Web of Science ®Google Scholar
• O’BrienSGuilhotFGoldmanJInternational randomized study of interferon versus ST1571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (PTS) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Abstract 18650th American Society of Hematology Annual Meeting and ExpositionDecemeber 6–9, 2008San Francisco, CA.
   Google Scholar
• DeiningerMO’BrienSGuilhotFInternational randomized study of interferon vs ST1571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Abstract 112651st American Society of Hematology Annual Meeting and ExpositionDecemeber 5–8, 2009New Orleans, LA
   Google Scholar
• HughesTPHochhausABranfordSLong-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood2010116193758376520679528
   PubMed Web of Science ®Google Scholar
• GuilhotFLarsonJO’BrienSGTime to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy49th American Society of Hematology Annual Meeting and ExpositionDecemeber 8–11, 2007Atlanta, GA
   Google Scholar
• ShahNKantarjianHHochhausACortesJBradley-GarelikMBZhuCDasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18 month follow-up. Abstract 20652nd American Society of Hematology Annual MeetingDecemeber 4–7, 2010Orlando, FL
   Google Scholar
• KantarjianHMShahNPCortesJEDasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood201211951123112922160483
   PubMed Web of Science ®Google Scholar
• HughesTHochhausASaglioGENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)52nd American Society of Hematology Annual MeetingDecember 4–7, 2010Orlando, FL
   Google Scholar
• HughesPHochhausASaglioGENESTnd 24-month update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)Blood2010116Abstr 207
   Web of Science ®Google Scholar
• KantarjianHMHochhausASaglioGNilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialLancet Oncol201112984185121856226
   PubMed Web of Science ®Google Scholar
• CortesJEMaruAAntonio de SouzaCBosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia– BELA trial: 24-month follow-up53rd American Society of Hematology Annual Meeting and ExpositionDecember 10–13, 2011San Diego, CA
   Google Scholar
• BaccaraniMRostiGCastagnettiFComparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyBlood2009113194497450419264678
   PubMed Web of Science ®Google Scholar
• LiptonJHTraskPCCellaDHealth-related quality of life in newly diagnosed chronic phase chronic myelogenous leukemia patients treated with bosutinib or imatinibAmerican Society of Clinical Oncology Annual MeetingJune 3–7, 2011Chicago, IL
   Google Scholar
• KantarjianHMGilesFJBhallaKNNilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsBlood201111741141114521098399
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHMBrummendorfTHSafety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinibBlood201111874567457621865346
   PubMed Web of Science ®Google Scholar
• SaglioGHochhausAGohYTDasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice dailyCancer2010116163852386120564086
   PubMed Web of Science ®Google Scholar
• ShahNPKimDWKantarjianHPotent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibHaematologica201095223224020139391
   PubMed Web of Science ®Google Scholar
• ShahNKimDWKantarjianHDasatinib dose-optimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose. Abstract 322552nd American Society of Hematology Annual MeetingDecember 4–7, 2010Orlando, FL
   Google Scholar
• ShahNCortesJSchifferCAFour-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. Abstract 6512American Society of Clinical Oncology Annual MeetingJune 4–8, 2010Chicago, IL
   Google Scholar
• ShahNCortesJSchifferCFive-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinibAmerican Society of Clinical Oncology Annual MeetingJune 3–7, 2011Chicago, IL
   Google Scholar
• KhouryHJCortesJEKantarjianHMBosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood2012119153403341222371878
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHO’BrienSThe achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsBlood2011118174541454621803854
   PubMed Web of Science ®Google Scholar
• MahonFXReaDGuilhotJDiscontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialLancet Oncol201011111029103520965785
   PubMed Web of Science ®Google Scholar
• SignorovitchJEWuEQBettsKAComparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trialsCurr Med Res Opin20112761263127121524239
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWPinilla-IbarzJInitial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutationPresented at 53rd American Society Hematology Annual MeetingDecember 10–13, 2011Atlanta, GA
   Google Scholar